610 Shares in Incyte Co. (NASDAQ:INCY) Bought by Bradley & Co. Private Wealth Management LLC

Bradley & Co. Private Wealth Management LLC purchased a new stake in Incyte Co. (NASDAQ:INCY) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 610 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

Other hedge funds also recently made changes to their positions in the company. CWA Asset Management Group LLC bought a new position in Incyte during the fourth quarter worth $1,933,000. Orion Portfolio Solutions LLC acquired a new position in shares of Incyte in the 3rd quarter valued at about $770,000. Greenwood Capital Associates LLC bought a new stake in Incyte in the third quarter worth approximately $433,000. Tri Ri Asset Management Corp acquired a new position in Incyte in the third quarter valued at approximately $3,292,000. Finally, Cypress Capital Group bought a new position in shares of Incyte during the 3rd quarter worth approximately $971,000. 96.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Incyte news, EVP Vijay K. Iyengar sold 6,043 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $75.38, for a total value of $455,521.34. Following the transaction, the executive vice president now directly owns 30,658 shares in the company, valued at $2,311,000.04. The trade was a 16.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the transaction, the executive vice president now directly owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 19,695 shares of company stock valued at $1,444,356. 17.60% of the stock is owned by insiders.

Incyte Trading Up 0.5 %

NASDAQ:INCY opened at $74.40 on Wednesday. Incyte Co. has a 52 week low of $50.35 and a 52 week high of $83.95. The firm has a 50-day moving average price of $71.42 and a two-hundred day moving average price of $69.70. The firm has a market cap of $14.40 billion, a price-to-earnings ratio of 275.57, a price-to-earnings-growth ratio of 0.41 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, equities analysts expect that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on INCY shares. Royal Bank of Canada lowered their price objective on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a research note on Tuesday, February 11th. Wells Fargo & Company upped their price objective on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. JMP Securities restated a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. StockNews.com downgraded Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. raised their price objective on Incyte from $65.00 to $71.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $75.25.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.